Alkermes
immune modulation in oncology based on engineered have pleiotropic effects and can act on every phase of the cancer immunity cycle alkermes is focusing on based therapies designed to increase visibility of tumor cells to immune system increase tumor killing potential of and cells mutation fusion remove suppressive signals in the tumor modern based drugs need a high degree of engineering to reduce side effects improve enhance efficacy natural killer journal of cancer cycle | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
52 of 144
Related slides by other companies
Genprex
Investor Presentation
October 2022
modulates the immune system | Genprex
Genprex
Investor Presentation
October 2022
in small cell lung cancer | Genprex
Genelux
Investor Presentation
December 2023
a maturing modality with phase companies validating potential gene | Genelux
Exscientia
Investor Presentation
October 2023
malt inhibition of immune cell signalling | Exscientia
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io